<DOC>
	<DOCNO>NCT02255227</DOCNO>
	<brief_summary>This multicenter , prospective , randomize , open study compare two anti-pneumococcal vaccination strategy patient Chronic Inflammatory Bowel Disease ( CIBD ) treat immunosuppressant and/or biotherapies . At present patient poorly protect anti-pneumococcal vaccination . In addition , vaccination efficacy type patient much weak general population . There two type anti-pneumococcal vaccine : firstly polysaccharide , Pneumo23® ( PSV-23® ) vaccine secondly conjugate , Prevenar13® vaccine . New recommendation issue HSCP advise immunocompromised patient follow vaccination plan combine one dose Prevenar13® follow one dose PSV-23® interval two month . In case young child infect HIV , recommendation multiply dose Prevenar13® PSV-23® injection improve vaccine efficacy immunocompromised patient . Our study aim identify optimal vaccination strategy immunocompromised CIBD patient combine use conjugate vaccine , Prevenar13® polysaccharide vaccine , PSV-23® . We compare use one two dos ( M0 +/- M2 ) Prevenar13® combine later PSV-23® injection ( M4 ) vaccination immunogenicity measure antibody titer least nine thirteen pneumococcal serotypes contain Prevenar13® . We also want evaluate immunological impact different strategy capacity stimulate memory B anti-pneumococcal response effectively . With aim , study immunological functional aspect antibody B lymphocytes induced two vaccine strategy .</brief_summary>
	<brief_title>Anti-pneumococcal Vaccine Strategy Patients Treated With Immunosuppressants Biotherapies CIBD</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Patient give write consent free inform consent Patient follow inflammatory bowel disease ( Crohn 's disease , ulcerative colitis indeterminate colitis ) , treat least 3 month immunosuppressive therapy /or biotherapies clinical remission least 3 month Patient agree participate study throughout duration accept procedure relate study Contraception investigator judge effective first 12 month trial , negative pregnancy test Women plan become pregnant 12 month follow inclusion ( M0 ) Patient social coverage Patients vaccinate pneumo23 less 5 year Other vaccination month inclusion Patient develop febrile illness ( least 37 ° C 5 measure orally ) acute infection week vaccination The patient flare IBD day vaccination ( HarveyBrasdshaw score least 6 CDAI &gt; 220 Crohn 's disease Mayo Clinic score least 4 UC indeterminate colitis ) Patients ongoing pregnancy day vaccination Patient know history neuropathy GuillainBarré syndrome . Patients know infection HIV / HBV ( HBsAg positive ) / HCV Patient severe immune deficiency Patients receive immunoglobulin infusion blood product , monoclonal antibody ( except antiTNF ) 3 month prior vaccination Patient institutionalize , deprive liberty administrative judicial Patients treat without immunosuppressive therapy biotherapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>vaccination</keyword>
	<keyword>randomize</keyword>
	<keyword>anti-pneumococcal</keyword>
	<keyword>Pneumo 23</keyword>
	<keyword>Prevenar 13</keyword>
	<keyword>Chronic Inflammatory Bowel Disease</keyword>
</DOC>